Lexicon Pharmaceuticals, Inc. (LXRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:21AM EDT. Market open.
| Previous close | 1.6000 |
| Open | 1.5900 |
| Bid | 1.5300 x 100 |
| Ask | 1.5500 x 400 |
| Day's range | 1.5200 - 1.5900 |
| 52-week range | 0.9200 - 3.7900 |
| Volume | |
| Avg. volume | 4,693,130 |
| Market cap | 377.974M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
- Zacks
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.